Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients from AIDS Malignancies Consortium Clinical Trials 010 and 034

Journal of Clinical Oncology

Volumn 27, Issue 30, 2009, Pages 5039-5048

  Chadburn, Amy ^a   Chiu, April ^a   Lee, Jeannette Y ^a   Chen, Xia ^a   Hyjek, Elizabeth ^a   Banham, Alison H ^a   Noy, Ariela ^a   Kaplan, Lawrence D ^a   Sparano, Joseph A ^a   Bhatia, Kishor ^a   Cesarman, Ethel ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; EVENT FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR CLASSIFICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KI-67 ANTIGEN; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77649088435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.5450     Document Type: Article

References (46)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
2. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
3. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000
4. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
5. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:13520-13525, 2008
6. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. Nat Med 8:68-74, 2002
7. Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861, 2005
8. Hans CP, Weisenburger DD, Vose JM, et al: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363-2367, 2003
9. Amen F, Horncastle D, Elderfield K, et al: Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology 51:70-79, 2007
10. Chang CC, McClintock S, Cleveland RP, et al: Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464-470, 2004
11. van Imhoff GW, Boerma EJ, van der Holt B, et al: Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24:4135-4142, 2006
12. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930-4935, 2007
13. Wilson WH, Dunleavy K, Pittaluga S, et al: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-2724, 2008
14. Grogan TM, Lippman SM, Spier CM, et al: Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71:1157-1160, 1988
15. Miller TP, Grogan TM, Dahlberg S, et al: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83:1460-1466, 1994
16. Sanchez E, Chacon I, Plaza MM, et al: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16:1931-1939, 1998
17. Wilson WH, Teruya-Feldstein J, Fest T, et al: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609, 1997
18. Jerkeman M, Anderson H, Dictor M, et al: Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma: A Nordic Lymphoma Group study. Ann Hematol 83:414-419, 2004
19. Sjö LD, Poulsen CB, Hansen M, et al: Profiling of diffuse large B-cell lymphoma by immunohistochemistry: Identification of prognostic subgroups. Eur J Haematol 79:501-507, 2007
20. Veelken H, Vik Dannheim S, Schulte Moenting J, et al: Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 18:931-939, 2007
21. Shivakumar L, Armitage JO: Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma 6:455-457, 2006
22. Little RF, Pittaluga S, Grant N, et al: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653-4659, 2003
23. Banham AH, Connors JM, Brown PJ, et al: Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072, 2005
24. Barrans SL, Fenton JA, Banham A, et al: Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933-2935, 2004
25. Shaffer AL, Rosenwald A, Staudt LM: Lymphoid malignancies: The dark side of B-cell differentiation. Nat Rev Immunol 2:920-932, 2002
26. Brown PJ, Ashe SL, Leich E, et al: Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111:2816-2824, 2008
27. Martins G, Calame K: Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 26:133-169, 2008
28. Nutt SL, Fairfax KA, Kallies A: BLIMP1 guides the fate of effector B and T cells. Nat Rev Immunol 7:923-927, 2007
29. Garcia JF, Roncador G, Garcia JF, et al: PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 91:467-474, 2006
30. Goedert JJ: The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 27:390-401, 2000
31. Carbone A, Gloghini A, Larocca LM, et al: Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97:744-751, 2001
32. Madan R, Gormley R, Dulau A, et al: AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. Mod Pathol 19:438-446, 2006
33. Hoffmann C, Tiemann M, Schrader C, et al: AIDS-related B-cell lymphoma (ARL): Correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 106:1762-1769, 2005
34. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005
35. Levine AM, JL, Kaplan L, et al: Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034. J Clin Oncol 26:460s, 2008 (suppl; abstr 8527)
36. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
37. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
38. Carbone A: Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 4:22-29, 2003
39. Biggar RJ, Chaturvedi AK, Goedert JJ, et al: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99:962-972, 2007
40. Engels EA, Biggar RJ, Hall HI, et al: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008
41. Sparano JA: HIV-associated lymphoma: The evidence for treating aggressively but with caution. Curr Opin Oncol 19:458-463, 2007
42. Gates AE, Kaplan LD: AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park) 16:441-451, 456, 459, 2002
43. Hishima T, Oyaizu N, Fujii T, et al: Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect 8:1301-1307, 2006
44. Kersten MJ, Van Gorp J, Pals ST, et al: Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: Correlation with histology and CD4-cell number. Leuk Lymphoma 30:515-524, 1998
45. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al: Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320-322, 1991
46. Rea D, Delecluse HJ, Hamilton-Dutoit SJ, et al: Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas: French Study Group of Pathology for HIV-associated Tumors. Ann Oncol 5:113-116, 1994 (suppl 1)